title: Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
abstract: To investigate the effect of altered oestrogen receptor (ER)alpha and ERbeta expression on oestrogen and anti-oestrogen action in breast cancer, we have stably expressed an inducible ERbeta1 in MCF7 breast cancer cells. Stably expressing clones were isolated and over-expression of ERbeta1 correlated with increased levels of specific radiolabelled oestradiol (E2) binding. Increased ERbeta1 did not affect endogenous levels of ERalpha but increased progesterone receptor (PR) levels. Over-expression of ERbeta1 reduced growth responses to E2 in contrast to little if any effect of over-expression of ERalpha. In oestrogen-replete conditions, over-expression of ERbeta1 but not ERalpha reduced proliferation. Over-expression of ERbeta1 did not result in anti-oestrogen resistance but was associated with increased sensitivity to 4-hydroxytamoxifen. Our results suggested that over-expression of ERbeta1 in the presence of an endogenously expressed ERalpha was associated with tamoxifen sensitivity but may negatively modulate ERalpha-mediated growth. However, not all ERalpha activities were inhibited since endogenous PR expression was increased by both ERalpha and ERbeta1 over-expression. These data paralleled those seen in some in vivo studies showing a relationship between PR and ERbeta expression as well as ERbeta expression and tamoxifen sensitivity of ER-positive breast cancer patients. These models are relevant and will be useful for dissecting the role of ERbeta1 expression in ER-positive breast cancer.
authors.affiliation: Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada. lcmurph@cc.umanitoba.ca
authors.forename: L C
authors.initials: LC
authors.lastname: Murphy
authors.forename: B
authors.initials: B
authors.lastname: Peng
authors.forename: A
authors.initials: A
authors.lastname: Lewis
authors.forename: J R
authors.initials: JR
authors.lastname: Davie
authors.forename: E
authors.initials: E
authors.lastname: Leygue
authors.forename: A
authors.initials: A
authors.lastname: Kemp
authors.forename: K
authors.initials: K
authors.lastname: Ung
authors.forename: M
authors.initials: M
authors.lastname: Vendetti
authors.forename: R
authors.initials: R
authors.lastname: Shiu
mesh_terms: D000900:Anti-Bacterial Agents / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004318:Doxycycline / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D000939:Epitopes; D047628:Estrogen Receptor alpha / Q000235:genetics / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000235:genetics / Q000378:metabolism*; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D015335:Molecular Probes / Q000378:metabolism; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism; D013629:Tamoxifen / Q000378:metabolism* / Q000627:therapeutic use; D015854:Up-Regulation
chemical_list: D000900:Anti-Bacterial Agents; D000939:Epitopes; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D004967:Estrogens; D015335:Molecular Probes; D020033:Protein Isoforms; D011980:Receptors, Progesterone; D013629:Tamoxifen; D004318:Doxycycline